Novel investigational drugs targeting IL-6 signaling for the treatment of depression
The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Elevated levels of IL-6 have been implicated in the pathophysiology and treatment of major depressive disorder (MDD). Convergent evidence suggests that IL-6 primarily mediates proinflammatory functions via the soluble IL-6 receptor/trans-signaling, and anti-inflammatory functions via a transmembrane receptor (IL-6R). A targeted approach to selectively inhibit IL-6 trans-signaling may offer putative antidepressant effects. AREAS COVERED: This review addresses three primary domains. The first focuses on the biological role of IL-6 within inflammation and its signal transduction pathways. The second addresses the potential contributions of IL-6 to the pathophysiology of MDD, and the mechanisms that may mediate these effects. Finally, the article outlines the therapeutic benefits of incorporating anti-inflammatory properties into the pharmacological treatment of MDD, and proposes inhibition of IL-6 signaling as a viable treatment strategy. EXPERT OPINION: To improve drug development for the treatment of MDD, there is a critical need to identify promising targets. Target identification will require guidance from a strategic framework such as The Research Domain Criteria, and convincing evidence relating known targets to brain function under both physiological and pathological conditions. Although current evidence provides rationale for administering anti-IL-6 treatments in MDD, further studies confirming safety, target affinity and therapeutic benefits are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
From inflammation to sickness and depression: when the immune system subjugates the brain
Dantzer, R., O'Connor, J. C., Freund, G. G., Johnson, R. W., & Kelley, K. W. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2297 · Cited by 7,395
The pro- and anti-inflammatory properties of the cytokine interleukin-6
Scheller, J., Chalaris, A., Schmidt-Arras, D., & Rose-John, S. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.01.034 · Cited by 3,212 · cited 6×
“These kinases activate the transcription factor STAT3 via phosphorylation, which results in the translocation of STAT3 into the nucleus to initiate gene expression [22,23].”
BackgroundInfluentialCytokines sing the blues: inflammation and the pathogenesis of depression
Raison, C. L., Capuron, L., & Miller, A. H. (2006) · Trends in Immunology · doi:10.1016/j.it.2005.11.006 · Cited by 3,009
Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis.
Howren, M. B., Lamkin, D. M., & Suls, J. (2009) · Psychosomatic Medicine · doi:10.1097/psy.0b013e3181907c1b · Cited by 2,766
The HPA axis in major depression: classical theories and new developments
Pariante, C. M., & Lightman, S. L. (2008) · Trends in Neurosciences · doi:10.1016/j.tins.2008.06.006 · Cited by 2,009
Raison, C. L., Rutherford, R. E., Woolwine, B. J., Shuo, C., Schettler, P., Drake, D. F., Haroon, E., & Miller, A. H. (2013) · JAMA Psychiatry · doi:10.1001/2013.jamapsychiatry.4 · Cited by 1,617 · cited 3×
“[127], which identified that previously treatment-resistant depressed patients with elevated CRP levels were more likely to respond to infliximab than were similarly depressed patients with low CRP levels.”
BackgroundResultInfluentialCytokine-Associated Emotional and Cognitive Disturbances in Humans
Reichenberg, A., Yirmiya, R., Schuld, A., Kraus, T., Haack, M., Morag, A., & Pollmächer, T. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.5.445 · Cited by 1,365 · cited 1×
“Proinflammatory cytokine activation in healthy individuals is likewise associated with disturbances in affect and cognition [53,54].”
BackgroundCytokines and major depression
Schiepers, O. J. G., Wichers, M. C., & Maes, M. (2005) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2004.11.003 · Cited by 1,235 · cited 2×
“The theory of cytokine-induced depression is based on the concept that proinflammatory cytokines function as neuromodulators within the CNS to produce the behavioral, neuroendocrine and neurochemical features of depressive disorders [46].”
BackgroundFerrari, A. J., Somerville, A. J., Baxter, A. J., Norman, R., Patten, S. B., Vos, T., & Whiteford, H. A. (2013) · Psychological Medicine · doi:10.1017/s0033291712001511 · Cited by 1,230 · cited 1×
“Major depressive disorder (MDD) is a highly debilitating psychiatric condition, with a global prevalence rate of ~ 4 -- 5% [1,2].”
BackgroundRose-John, S. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.4989 · Cited by 1,040 · cited 5×
“The IL-6/sIL-6R complex affects a wider range of target cells such as endothelial cells, neuronal cells, osteoclasts, hematopoietic progenitor cells and embryonic stem cells [37,41].”
BackgroundInfluential
Cited by
Zhang, J.-C., Yao, W., & Hashimoto, K. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666160119094646 · Cited by 538
“This makes it unlikely that brain-derived IL-6 might be involved in the pathogenesis of depression [63, 64].”
Role of IL-6 in the regulation of neuronal development, survival and function
Kummer, K. K., Zeidler, M., Kalpachidou, T., & Kress, M. (2021) · Cytokine · doi:10.1016/j.cyto.2021.155582 · Cited by 278
Role of Inflammation in Suicide: From Mechanisms to Treatment
Brundin, L., Bryleva, E. Y., & Thirtamara Rajamani, K. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.116 · Cited by 257
“Previous studies have found that tocilizumab is able to effectively treat several inflammatory and autoimmune diseases (Choy et al , 2002; Fonseka et al , 2015; Ito et al , 2004) and a recently initiated RCT will access the ability of tocilizumab to decrease depressive symptomology in…”
Zhang, J.-C., Yao, W., Dong, C., Yang, C., Ren, Q., Ma, M., & Hashimoto, K. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.112 · Cited by 182
Atli, A., Demir, S., Bulut, M., Okan İbiloğlu, A., Güneş, M., Kaya, M., Demirpençe, Ö., & Sır, A. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s89470 · Cited by 156
Metadata
- Authors
- Fonseka, T. M., McIntyre, R. S., Soczynska, J. K., & Kennedy, S. H.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2015-01-14
- Volume
- 24
- Issue
- 4
- Pages
- 459-475
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2129376177
- Cited by
- 54
- References
- 73
- FWCI
- 5.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Novel investigational drugs targeting IL-6 signaling for the treatment of depression. https://app.cochat.ai/papers/10.1517/13543784.2014.998334
- The paper
- Fonseka, T. M., McIntyre, R. S., Soczynska, J. K., & Kennedy, S. H. (2015). Novel investigational drugs targeting IL-6 signaling for the treatment of depression. Expert Opinion on Investigational Drugs. https://doi.org/10.1517/13543784.2014.998334
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.